The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Biocompatible Synthetic Conduits To Treat Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$421,818.00
Summary
Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular diseas ....Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular disease.Read moreRead less
Innovative Antimicrobial Treatments For Successful Bone Allografts
Funder
National Health and Medical Research Council
Funding Amount
$473,706.00
Summary
Bone healing sites are commonly infected, and this is associated with adverse clinical and significant socioeconomic outcomes. These studies will determine whether our novel antimicrobials can be used to reduce bone infections by studying the combination of antimicrobials and bone in laboratory and bone fracture studies whilst minimising the potential of developing antibiotic resistance.
Bioactive And Biodegradable Scaffold And Novel Graft Source For The Repair Of Large Segmental Bone Defects
Funder
National Health and Medical Research Council
Funding Amount
$451,103.00
Summary
The treatment of large bone defects arising from trauma and tumour remains a challenge to orthopaedic surgeons. This project combines a well-established scaffold that can be custom-made to address patient specific requirements with a novel source of graft that can be harvested in significant volumes with minimal pain and morbidity. This novel tissue engineering approach will be evaluated in a previously established pre-clinical model that reflects the severity of challenging clinical scenarios.
Organ transplantation is the measure of last resort for patients with organ failure. While this is a life-saving procedure, the long-term survival of transplant recipients depends on maintaining the new organ without rejecting it. The proposed research will create novel test systems that allow both patients and clinicians to monitor the concentration of the drugs required to suppress organ rejection. Such a test will reduce the cost of treatment and increase the long term survival of patients.
Peptide Therapeutics For The Treatment Of Autoimmune Diseases: Stability, Delivery And Disposition
Funder
National Health and Medical Research Council
Funding Amount
$368,467.00
Summary
Autoimmune diseases affect around 120 million people worldwide. This project will progress the development of a peptide that suppresses disease-causing autoantigen-specific immune responses without affecting protective responses. Different routes of delivery for this peptide will be evaluated, as well as slow-release formulations that will extend its in vivo lifetime. The outcome will be a patient-friendly form of this therapeutic lead that can be taken forward to preclinical evaluation.
A vitamin-sized capsule, containing gas sensors, is to be fully developed for assessing the state of health and diagnosing the diseases relevant to gastrointestinal tract. The capsule travels along the tract, transmitting information about the gas species generated by the microorganisms of the gut, which is closely associated with the health of the human under surveillance. The information will be invaluable for diagnostics and adjusting the diet to mitigate and cure the diseases of the guts.
Enhanced Deep Brain Stimulation Electrodes For Improved Efficacy In Parkinson’s Disease Therapy
Funder
National Health and Medical Research Council
Funding Amount
$809,940.00
Summary
We are developing an advanced Deep Brain Stimulation system to improve the treatment for Parkinson’s disease. Current devices benefit only half of the patients, due to imprecision in directing the electrical current to the ideal brain targets. Our system aims to deliver the current more selectively. Our implant will contain more and smaller electrodes. We will also use a state-of-the-art stimulator, implantable on the head, with capabilities far beyond the current technology.
Evaluation Of The Safety Of Lead Compounds For Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$310,568.00
Summary
Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.
Fighting Blindness With A Minimally Invasive Retinal Stimulator
Funder
National Health and Medical Research Council
Funding Amount
$998,194.00
Summary
Retinal degenerative conditions are the leading cause of blindness in developed nations, with over 200 million people afflicted worldwide. Our group has pioneered a minimally-invasive therapeutic stimulator that can arrest retinal degeneration without blocking vision. We are now ready to perform the prerequisite translational studies to develop and test a human-grade device. The ultimate goal is to be the first to develop a commercial therapeutic stimulator that protects against vision loss.
Development Of A Novel Endovascular Therapy For Occlusive Peripheral Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$624,197.00
Summary
We aim to develop and assess a new medical device for the treatment of diseased arteries. The new device uses an angioplasty balloon coated with a new drug to open narrowed arteries and will enable the arteries to remain open for longer periods and with less likelihood of unwanted side effects from the procedure.